Table 3 Pooled sensitivity analyses of hormone replacement therapy after diagnosis and cancer-specific mortality in England, Scotland and Wales.

From: Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records

Analysis

Cancer- deaths

Person-years

Unadjusted HR (95% CI)

Adjustede HR (95% CI)

Colorectal

  Main analysisa

8481

178687

0.80 (0.70, 0.91)

0.79 (0.70, 0.90)

  Using 1 year lag

6451

162372

0.85 (0.75, 0.97)

0.83 (0.73, 0.95)

  HRT versus vaginal oestrogen therapyb

528

22942

0.98 (0.82, 1.17)

0.93 (0.78, 1.10)

  Restricted to age 55 to 79

7216

151411

0.79 (0.68, 0.92)

0.82 (0.70, 0.95)

  Restricted to new HRT userc

7642

157327

0.85 (0.70, 1.02)

0.83 (0.69, 0.99)

  Restricted to stage 1 to 3d

3959

128031

0.84 (0.59, 1.19)

0.87 (0.68, 1.11)

  Adjusted for stage (MI)e

8481

178687

0.80 (0.70, 0.91)

0.82 (0.72, 0.92)

  Adjusted for stage (CC)f

6868

143268

0.83 (0.68, 1.02)

0.77 (0.63, 0.94)

Lung

  Main analysisa

16504

58215

0.97 (0.87, 1.08)

0.98 (0.90, 1.07)

  Using 1 year lag

9540

46988

0.97 (0.86, 1.09)

0.99 (0.88, 1.10)

  HRT versus vaginal oestrogen therapyb

806

5267

1.29 (1.10, 1.51)

1.18 (1.01, 1.39)

  Restricted to age 55 to 79

14839

51181

0.98 (0.89, 1.08)

0.99 (0.90, 1.09)

  Restricted to new HRT userc

14638

51437

0.88 (0.60, 1.29)

0.89 (0.72, 1.10)

  Restricted to stage 1 to 3d

5653

30872

0.90 (0.64, 1.27)

1.09 (0.85, 1.39)

  Adjusted for stage (MI)e

16504

58215

0.97 (0.87, 1.08)

0.99 (0.88, 1.12)

  Adjusted for stage (CC)f

11886

41971

1.01 (0.86, 1.19)

1.08 (0.88, 1.32)

Melanoma

  Main analysisa

1152

108702

0.68 (0.50, 0.93)

0.77 (0.58, 1.02)

  Using 1 year lag

995

100300

0.63 (0.45, 0.87)

0.69 (0.51, 0.92)

  HRT versus vaginal oestrogen therapyb

115

20604

1.03 (0.53, 1.99)

1.22 (0.69, 2.18)

  Restricted to age 55 to 79

840

66599

0.75 (0.37, 1.52)

0.88 (0.48, 1.63)

  Restricted to new HRT userc

1009

93485

0.78 (0.55, 1.12)

0.97 (0.68, 1.40)

  Restricted to stage 1 to 3d

421

49897

0.73 (0.47, 1.14)

0.96 (0.60, 1.52)

  Adjusted for stage (MI)e

1152

108702

0.68 (0.50, 0.93)

0.85 (0.66, 1.11)

  Adjusted for stage (CC)f

543

51361

0.64 (0.41, 0.99)

0.89 (0.59, 1.36)

Cervix

  Main analysisa

1213

30649

0.46 (0.34, 0.62)

0.82 (0.66, 1.02)

  Using 1 year lag

906

28011

0.47 (0.36, 0.61)

0.79 (0.62, 1.01)

  HRT versus vaginal oestrogen therapyb

134

9321

0.70 (0.27, 1.84)

1.11 (0.54, 2.27)

  Restricted to age 55 to 79

714

11423

0.39 (0.21, 0.74)

0.59 (0.31, 1.11)

  Restricted to new HRT userc

1083

27043

0.50 (0.37, 0.68)

0.90 (0.72, 1.14)

  Restricted to stage 1 to 3d

454

14126

0.49 (0.32, 0.76)

0.91 (0.65, 1.28)

  Adjusted for stage (MI)e

1213

30649

0.46 (0.34, 0.62)

0.98 (0.78, 1.24)

  Adjusted for stage (CC)f

940

21017

0.48 (0.33, 0.69)

0.98 (0.73, 1.32)

Ovary

  Main analysisa

6056

68868

0.39 (0.27, 0.57)

0.60 (0.39, 0.93)

  Using 1 year lag

4923

61547

0.38 (0.25, 0.58)

0.59 (0.36, 0.95)

  HRT versus vaginal oestrogen therapyb

439

13300

0.55 (0.31, 0.96)

0.74 (0.41, 1.33)

  Restricted to age 55 to 79

4936

44682

0.86 (0.70, 1.04)

0.88 (0.70, 1.11)

  Restricted to new HRT userc

5324

60248

0.29 (0.20, 0.42)

0.56 (0.36, 0.86)

  Restricted to stage 1 to 3d

2627

34050

0.37 (0.21, 0.66)

0.77 (0.63, 0.94)

  Adjusted for stage (MI)e

6056

68868

0.39 (0.27, 0.57)

0.75 (0.58, 0.97)

  Adjusted for stage (CC)f

4216

41807

0.38 (0.23, 0.65)

0.75 (0.58, 0.98)

  1. aAdjusted model contains age, year of diagnosis, deprivation, cancer treatment (surgery, radiotherapy, chemotherapy), Charlson comorbidities (before diagnosis), anaemia (before diagnosis), medication use (before diagnosis: statin, aspirin, metformin and oral contraceptive) and hysterectomy/oophorectomy (before or at diagnosis).
  2. bIndividuals not using HRT or vaginal oestrogen therapy excluded.
  3. cRestricted to patients not using systemic HRT in the period 18 to 6 months before cancer diagnosis.
  4. dRestricted to patients stage 1–3. Adjusted model contains all terms in a along with stage.
  5. eStage imputed using multiple imputation as described in methods. Adjusted model contains all terms in a along with stage.
  6. fRestricted to patients with available stage. Adjusting for stage using complete case, model contains all terms in a along with stage.
Back to article page